^
    Back
    Association details:
    Biomarker:BCR-ABL1 V299L
    Cancer:Acute Lymphocytic Leukemia
    Drug:Bosulif (bosutinib) (Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Regimens for relapsed or refractory Ph-positive ALL…Treatment options based on BCR-ABL1 mutation profile…Bosutinib…Contraindicated mutations...T315I, V299L, G250E, or F317L
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cell J
    Title:

    Exploiting temporal collateral sensitivity in tumor clonal evolution

    Excerpt:
    ...BCR-ABL1 V299L expectedly conferred resistance to dasatinib and bosutinib, we observed strong and robust sensitization to crizotinib, foretinib, cabozantinib, and vandetanib...
    DOI:
    https://dx.doi.org/10.1016%2Fj.cell.2016.01.045